You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pomalidomide, Imnovid, dexamethasone, Poseidon, multiple myeloma, daily routine, secondary malignancies, Germany, non-interventional study, safety,

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-interventional Study With Pomalidomide (Imnovid®)

Completed
  • Multiple Myeloma
    • Freiburg, Baden-Wuerttemberg, Germany
      iOMEDICO AG
    Aug 11, 2022

    Multiple Myeloma, Relapse, Refractory Trial in Chapel Hill, Winston-Salem, Columbus (Isatuximab, Pomalidomide, Dexamethasone)

    Not yet recruiting
    • Multiple Myeloma
    • +4 more
    • Chapel Hill, North Carolina
    • +2 more
    Jun 9, 2023

    Evaluation of POMALYST® Treatment of Multiple Myeloma in Korea

    Recruiting
    • Multiple Myeloma
    • POMALYST® (Pomalidomide)
    • Ansan, Korea, Republic of
    • +32 more
    Aug 17, 2022

    Relapsed or Refractory Multiple Myeloma Trial in Worldwide (Carfilzomib, Dexamethasone, Pomalidomide)

    Active, not recruiting
    • Relapsed or Refractory Multiple Myeloma
    • Birmingham, Alabama
    • +45 more
    Dec 6, 2022

    Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix, Jacksonville, Rochester

    Recruiting
    • Plasma Cell Myeloma
    • +3 more
    • Bone Marrow Biopsy
    • +3 more
    • Phoenix, Arizona
    • +2 more
    Jan 18, 2023

    Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Pomalidomide)

    Recruiting
    • Multiple Myeloma
    • Woolloongabba, Queensland, Australia
    • +117 more
    Aug 3, 2022

    Recurrent Plasma Cell Myeloma Trial in United States (Daratumumab, Dexamethasone, Pomalidomide)

    Withdrawn
    • Recurrent Plasma Cell Myeloma
    • Daratumumab
    • +2 more
    • Wichita, Kansas
    • +4 more
    Jun 13, 2022

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jun 3, 2022

    Multiple Myeloma Trial in Worldwide (JNJ-68284528, Pomalidomide, Bortezomib)

    Active, not recruiting
    • Multiple Myeloma
    • Birmingham, Alabama
    • +87 more
    Jan 17, 2023

    Selinexor in Relapsed or Refractory Multiple Myeloma - SEATTLE-

    Recruiting
    • Multiple Myeloma
    • Wien, Austria
    • +1 more
    Jul 13, 2023

    Plasma Cell Myeloma Trial in Atlanta (Belantamab Mafodotin, Dexamethasone, Pomalidomide)

    Recruiting
    • Plasma Cell Myeloma
    • Belantamab Mafodotin
    • +2 more
    • Atlanta, Georgia
      Emory University/Winship Cancer Institute
    Jul 21, 2022

    Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Pomalidomide, Dexamethasone)

    Recruiting
    • Multiple Myeloma
    • Belantamab mafodotin
    • +3 more
    • Tucson, Arizona
    • +131 more
    Jul 1, 2022

    Multiple Myeloma Trial in United States (Magrolimab, Daratumumab, Pomalidomide)

    Recruiting
    • Multiple Myeloma
    • Magrolimab
    • +5 more
    • Tucson, Arizona
    • +8 more
    Jul 28, 2022

    Relapsed/Refractory Multiple Myeloma Trial in Worldwide (AMG 701, Pomalidomide, Dexamethasone)

    Active, not recruiting
    • Relapsed/Refractory Multiple Myeloma
    • AMG 701
    • +2 more
    • Scottsdale, Arizona
    • +33 more
    Nov 29, 2022

    Relapsed/Refractory Multiple Myeloma Trial in La Jolla (Ixazomib, Pomalidomide, Dexamethasone)

    Recruiting
    • Relapsed/Refractory Multiple Myeloma
    • La Jolla, California
      UCSD Moores Cancer Center
    Mar 7, 2022

    Multiple Myeloma Trial in Hackensack (Daratumumab, Pomalidomide, All-trans retinoic acid)

    Recruiting
    • Multiple Myeloma
    • Hackensack, New Jersey
      John Theurer Cancer Center
    Jun 10, 2022

    Myeloma Trial in La Jolla, Orange, Sacramento (Clarithromycin, Dexamethasone, Ixazomib Citrate)

    Active, not recruiting
    • Myeloma
    • La Jolla, California
    • +2 more
    Mar 14, 2022

    Multiple Myeloma Trial in Milwaukee (Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide)

    Recruiting
    • Multiple Myeloma
    • Isatuximab (for run-in portion)
    • +4 more
    • Milwaukee, Wisconsin
      Froedtert Hospital & the Medical College of Wisconsin
    Feb 18, 2022

    Relapsed/Refractory Multiple Myeloma With Pomalidomide in

    Recruiting
    • Multiple Myeloma
    • Feldkirch, Austria
    • +12 more
    May 16, 2022

    Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)

    Recruiting
    • Plasma Cell Myeloma
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    Oct 5, 2021

    Multiple Myeloma Trial in Worldwide (Elotuzumab, Pomalidomide, Dexamethasone)

    Completed
    Has Results
    • Multiple Myeloma
    • Atlanta, Georgia
    • +54 more
    Jan 11, 2022

    Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Elotuzumab, Pomalidomide)

    Suspended
    • Refractory Plasma Cell Myeloma
    • Jacksonville, Florida
      Mayo Clinic in Florida
    Oct 18, 2021

    Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,

    Active, not recruiting
    Has Results
    • Refractory Plasma Cell Myeloma
    • Recurrent Plasma Cell Myeloma
    • ixazomib citrate
    • +2 more
    • Scottsdale, Arizona
    • +4 more
    Mar 28, 2022

    Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma Trial in Worldwide (CCS1477, Pomalidomide,

    Recruiting
    • Haematological Malignancy
    • +4 more
    • Phoenix, Arizona
    • +14 more
    Aug 22, 2022

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jun 14, 2022